Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Veru Inc

Market Cap 47.99M 41.4M 38.06M 35.83M 67.32M 4.53B 67.89M 451M 176M 2.22B 180M 176M 7.69B P/E 2026 *
-2.95x
P/E 2027 * -3.04x
Enterprise Value 47.99M 41.4M 38.06M 35.83M 67.32M 4.53B 67.89M 451M 176M 2.22B 180M 176M 7.69B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.01%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 2016-10-30
Director of Finance/CFO 67 2012-12-31
Chief Tech/Sci/R&D Officer 64 2018-03-31
Director TitleAgeSince
Chairman 65 2018-02-28
Director/Board Member 68 2016-09-30
Director/Board Member 68 2018-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%+14.29% - - 47.99M
+0.46%+1.08%+65.82%+117.72% 56.24B
+0.04%+1.20%+47.67%+36.75% 43.76B
+3.04%+7.05%-12.15%-18.06% 23.32B
+3.07%+7.15%-1.82%+392.25% 21.34B
+3.22%+2.94%+24.02%-34.00% 15.75B
+0.79%+2.01%+16.41%-37.59% 15.6B
+0.65%-0.27%+26.80%+174.70% 13.18B
+3.07%+5.43%+21.37% - 12.01B
+1.92%+2.43%+112.68%+232.59% 11.87B
Average +1.77%+3.15%+33.42%+108.04% 23.68B
Weighted average by Cap. +1.40%+2.96%+37.77%+100.07%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.65M -19.91M -18.74M -35.21M -2.37B -35.51M -236M -91.85M -1.16B -94.21M -92.19M -4.02B -37.1M -32.01M -29.43M -27.7M -52.04M -3.5B -52.48M -349M -136M -1.72B -139M -136M -5.94B
Net Debt - -
Logo Veru Inc
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!